<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39431150</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2328-8957</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Open forum infectious diseases</Title><ISOAbbreviation>Open Forum Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Diagnostic Utility of SARS-CoV-2 Nucleocapsid Antigenemia: A Meta-analysis.</ArticleTitle><Pagination><StartPage>ofae561</StartPage><MedlinePgn>ofae561</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ofae561</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ofid/ofae561</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Studies of the diagnostic performance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid antigen in blood (antigenemia) have reached variable conclusions. The potential utility of antigenemia measurements as a clinical diagnostic test needs clarification.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We performed a systematic review of Pubmed, Embase, and Scopus through July 15, 2023, and requested source data from corresponding authors.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Summary sensitivity from 16 studies (4543 cases) sampled at ≤14 days of symptoms was 0.83 (0.75-0.89), and specificity was 0.98 (0.87-1.00) from 6 studies (792 reverse transcription polymerase chain reaction-negative controls). Summary sensitivity and specificity for paired respiratory specimens with cycle threshold values ≤33 were 0.91 (0.85-0.95) and 0.56 (0.39-0.73) from 10 studies (612 individuals). Source data from 1779 cases reveal that &gt;70% have antigenemia 2 weeks following symptom onset, which persists in &lt;10% at 28 days. The available studies suffer from heterogeneity, and Omicron-era data are scarce.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Nucleocapsid antigenemia currently has limited utility due to limitations of existing studies and lack of Omicron-era data. Improved study designs targeting potential clinical uses in screening, surveillance, and complex clinical decision-making-especially in immunocompromised patients-are needed.</AbstractText><CopyrightInformation>© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Damhorst</LastName><ForeName>Gregory L</ForeName><Initials>GL</Initials><Identifier Source="ORCID">0000-0002-2237-1713</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, Emory University, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Atlanta Center for Microsystems-Engineered Point-of-Care Technologies, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Sydney E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilber</LastName><ForeName>Eli</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-8413-2681</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, Emory University, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verkerke</LastName><ForeName>Hans</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Emory University School of Medicine, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goodman</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6956-6879</Identifier><AffiliationInfo><Affiliation>Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>Wilbur A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>The Atlanta Center for Microsystems-Engineered Point-of-Care Technologies, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Aflac Cancer &amp; Blood Disorders Center at Children's Healthcare of Atlanta, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Open Forum Infect Dis</MedlineTA><NlmUniqueID>101637045</NlmUniqueID><ISSNLinking>2328-8957</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antigenemia</Keyword><Keyword MajorTopicYN="N">nucleocapsid</Keyword></KeywordList><CoiStatement>Potential conflicts of interest. The authors have no conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>16</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39431150</ArticleId><ArticleId IdType="pmc">PMC11487748</ArticleId><ArticleId IdType="doi">10.1093/ofid/ofae561</ArticleId><ArticleId IdType="pii">ofae561</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Che  X-Y, Hao  W, Wang  Y, et al.  Nucleocapsid protein as early diagnostic marker for SARS. Emerg Infect Dis  2004; 10:1947–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3329003</ArticleId><ArticleId IdType="pubmed">15550204</ArticleId></ArticleIdList></Reference><Reference><Citation>Che  XY, Qiu  LW, Pan  YX, et al.  Sensitive and specific monoclonal antibody-based capture enzyme immunoassay for detection of nucleocapsid antigen in sera from patients with severe acute respiratory syndrome. J Clin Microbiol  2004; 42:2629–35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC427886</ArticleId><ArticleId IdType="pubmed">15184444</ArticleId></ArticleIdList></Reference><Reference><Citation>Di  B, Hao  W, Gao  Y, et al.  Monoclonal antibody-based antigen capture enzyme-linked immunosorbent assay reveals high sensitivity of the nucleocapsid protein in acute-phase sera of severe acute respiratory syndrome patients. Clin Diagn Lab Immunol  2005; 12:135–40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC540218</ArticleId><ArticleId IdType="pubmed">15642998</ArticleId></ArticleIdList></Reference><Reference><Citation>Li  Y-H, Li  J, Liu  X-E, et al.  Detection of the nucleocapsid protein of severe acute respiratory syndrome coronavirus in serum: comparison with results of other viral markers. J Virol Methods  2005; 130:45–50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7112769</ArticleId><ArticleId IdType="pubmed">16024098</ArticleId></ArticleIdList></Reference><Reference><Citation>Che  XY, Di  B, Zhao  GP, et al.  A patient with asymptomatic severe acute respiratory syndrome (SARS) and antigenemia from the 2003–2004 community outbreak of SARS in Guangzhou, China. Clin Infect Dis  2006; 43:e1–5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7108013</ArticleId><ArticleId IdType="pubmed">16758408</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao  T, Gao  Y, Liu  X, et al.  Identification and functional analysis of the SARS-COV-2 nucleocapsid protein. BMC Microbiol  2021; 21:58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7898026</ArticleId><ArticleId IdType="pubmed">33618668</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai  Z, Cao  Y, Liu  W, Li  J. The SARS-CoV-2 nucleocapsid protein and its role in viral structure, biological functions, and a potential target for drug or vaccine mitigation. Viruses  2021; 13:1115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8227405</ArticleId><ArticleId IdType="pubmed">34200602</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang  Y, Chen  J, Chen  S, et al.  Molecular characterization of SARS-CoV-2 nucleocapsid protein. Front Cell Infect Microbiol  2024; 14:1415885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11153676</ArticleId><ArticleId IdType="pubmed">38846351</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathur  S, So  M, Tahir  P, Peluso  MJ, Martin  JN, Kelly  JD. Performance of blood-based nucleocapsid antigen tests for diagnosis of severe acute respiratory syndrome coronavirus 2 infection and infectious viral shedding: a systematic review. Open Forum Infect Dis  2023; 10:XXX–XX.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10400123</ArticleId><ArticleId IdType="pubmed">37547852</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahava  MJ, Kurkela  S, Kuivanen  S, Lappalainen  M, Jarva  H, Jaaskelainen  AJ. Detection of SARS-CoV-2 nucleocapsid antigen from serum can aid in timing of COVID-19 infection. J Virol Methods  2022; 302:114469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8762868</ArticleId><ArticleId IdType="pubmed">35051445</ArticleId></ArticleIdList></Reference><Reference><Citation>Blain  H, Tuaillon  E, Gamon  L, et al.  Receptor binding domain-IgG levels correlate with protection in residents facing SARS-CoV-2 B.1.1.7 outbreaks. Allergy  2022; 77:1885–94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8652754</ArticleId><ArticleId IdType="pubmed">34652831</ArticleId></ArticleIdList></Reference><Reference><Citation>Chenane  HR, Menidjel  R, Lebourgeois  S, et al.  SARS-CoV-2 N-antigen sera levels are associated with COVID-19 prognostic value [CROI abstract 197]. Top Antiv Med  2022; 30(1s).</Citation></Reference><Reference><Citation>Damhorst  GL, Verkerke  HP, Harrington  KRV, et al.  SARS-CoV-2 antigenemia is associated with pneumonia in children but lacks sensitivity to diagnose acute infection. Pediatr Infect Dis J  2023; 42:130–5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9838602</ArticleId><ArticleId IdType="pubmed">36638399</ArticleId></ArticleIdList></Reference><Reference><Citation>Damhorst  GL, Schoof  N, Nguyen  PV, et al.  Investigation of blood plasma viral nucleocapsid antigen as a marker of active severe acute respiratory syndrome coronavirus 2 omicron variant infection. Open Forum Infect Dis  2023; 10:XXX–XX.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10199120</ArticleId><ArticleId IdType="pubmed">37213426</ArticleId></ArticleIdList></Reference><Reference><Citation>Favresse  J, Bayart  JL, David  C, et al.  Serum SARS-CoV-2 antigens for the determination of COVID-19 severity. Viruses  2022; 14;1653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9415151</ArticleId><ArticleId IdType="pubmed">36016276</ArticleId></ArticleIdList></Reference><Reference><Citation>Favresse  J, Bayart  JL, David  C, Dogne  JM, Douxfils  J. Nucleocapsid serum antigen determination in SARS-CoV-2 infected patients using the single molecule array technology and prediction of disease severity. J Infect  2022; 84:e4–6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8779852</ArticleId><ArticleId IdType="pubmed">35074508</ArticleId></ArticleIdList></Reference><Reference><Citation>Hingrat  QL, Visseaux  B, Laouenan  C, et al.  Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives. Clin Microbiol Infect  2020; 27:789.e1–5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7724284</ArticleId><ArticleId IdType="pubmed">33307227</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal  NR, Nordwall  J, Der  T, et al.  Association and additive risk of respiratory and viral response baseline variables with mortality in therapeutics for inpatients with COVID-19 (TICO) platform randomized clinical trial (RCT) participants. Am J Respir Crit Care Med  2023; 207:A6556.</Citation></Reference><Reference><Citation>Li  T, Wang  L, Wang  H, et al.  Serum SARS-COV-2 nucleocapsid protein: a sensitivity and specificity early diagnostic marker for SARS-COV-2 infection. Front Cell Infect Microbiol  2020; 10:470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7498565</ArticleId><ArticleId IdType="pubmed">33014893</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogata  AF, Maley  AM, Wu  C, et al.  Ultra-sensitive serial profiling of SARS-CoV-2 antigens and antibodies in plasma to understand disease progression in COVID-19 patients with severe disease. Clin Chem  2020; 66:1562–72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7499543</ArticleId><ArticleId IdType="pubmed">32897389</ArticleId></ArticleIdList></Reference><Reference><Citation>Oueslati  S, Manai Bouokazi  M, Ramdhani  I, et al.  Clinical added value of SARS-CoV-2 antigen detection in blood samples. Diagnostics (Basel)  2022; 12;2427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9600523</ArticleId><ArticleId IdType="pubmed">36292116</ArticleId></ArticleIdList></Reference><Reference><Citation>Parraud  D, Maucotel  AL, Bouscambert  M, et al.  SARS-CoV-2 N-antigen quantification in respiratory tract, plasma and urine: kinetics and association with RT-qPCR results. Viruses  2023; 15:1041.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10221862</ArticleId><ArticleId IdType="pubmed">37243128</ArticleId></ArticleIdList></Reference><Reference><Citation>Perna  F, Bruzzaniti  S, Piemonte  E, et al.  Serum levels of SARS-CoV-2 nucleocapsid antigen associate with inflammatory status and disease severity in COVID-19 patients. Clin Immunol  2021; 226:108720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8017913</ArticleId><ArticleId IdType="pubmed">33819577</ArticleId></ArticleIdList></Reference><Reference><Citation>Group  A-TS, Rogers  AJ, Wentworth  D, et al.  The association of baseline plasma SARS-CoV-2 nucleocapsid antigen level and outcomes in patients hospitalized with COVID-19. Ann Intern Med  2022; 175:1401–10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9447373</ArticleId><ArticleId IdType="pubmed">36037469</ArticleId></ArticleIdList></Reference><Reference><Citation>Saini  P, Adeniji  OS, Bordoloi  D, et al.  Siglec-9 restrains antibody-dependent natural killer cell cytotoxicity against SARS-CoV-2. mBio  2023; 14:e0339322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9973332</ArticleId><ArticleId IdType="pubmed">36728420</ArticleId></ArticleIdList></Reference><Reference><Citation>Shan  D, Johnson  JM, Fernandes  SC, et al.  N-protein presents early in blood, dried blood and saliva during asymptomatic and symptomatic SARS-CoV-2 infection. Nat Commun  2021; 12:1931.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7997897</ArticleId><ArticleId IdType="pubmed">33771993</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigal  GB, Novak  T, Mathew  A, et al.  Measurement of severe acute respiratory syndrome coronavirus 2 antigens in plasma of pediatric patients with acute coronavirus disease 2019 or multisystem inflammatory syndrome in children using an ultrasensitive and quantitative immunoassay. Clin Infect Dis  2022; 75:1351–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8903440</ArticleId><ArticleId IdType="pubmed">35213684</ArticleId></ArticleIdList></Reference><Reference><Citation>Su  B, Yin  J, Lin  X, et al.  Quantification of SARS-CoV-2 antigen levels in the blood of patients with COVID-19. Sci China Life Sci  2021; 64:1193–6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7706695</ArticleId><ArticleId IdType="pubmed">33259038</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan  K, Zhuo  H, Caldwell  E, et al.  Plasma SARS-CoV-2 nucleocapsid antigen levels are associated with in-hospital mortality in hospitalized patients with COVID-19. Am J Respir Crit Care Med  2023; 207:A6235-A.</Citation></Reference><Reference><Citation>Swank  Z, Senussi  Y, Manickas-Hill  Z, et al.  Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post-acute coronavirus disease 2019 sequelae. Clin Infect Dis  2023; 76:e487–90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference><Reference><Citation>Thudium  RF, Stoico  MP, Hogdall  E, et al.  Early laboratory diagnosis of COVID-19 by antigen detection in blood samples of the SARS-CoV-2 nucleocapsid protein. J Clin Microbiol  2021; 59:e0100121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8451432</ArticleId><ArticleId IdType="pubmed">34260271</ArticleId></ArticleIdList></Reference><Reference><Citation>Verkerke  H, Harrington  K, McLendon  K, et al.  Longitudinal assessment of SARS-CoV-2 nucleocapsid antigenemia in patients hospitalized with COVID-19. Am J Clin Pathol  2021; 156(Suppl 1):S1.</Citation></Reference><Reference><Citation>Verkerke  HP, Damhorst  GL, Graciaa  DS, et al.  Nucleocapsid antigenemia is a marker of acute SARS-CoV-2 infection. J Infect Dis  2022; 226:1577–87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9384592</ArticleId><ArticleId IdType="pubmed">35877413</ArticleId></ArticleIdList></Reference><Reference><Citation>Veyrenche  N, Pisoni  A, Debiesse  S, et al.  Severe acute respiratory syndrome coronavirus 2 nucleocapsid antigen in urine of hospitalized patients with coronavirus disease 2019. J Infect Dis  2022; 226:812–21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8903449</ArticleId><ArticleId IdType="pubmed">35230450</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang  H, Hogan  CA, Verghese  M, et al.  SARS-CoV-2 nucleocapsid plasma antigen for diagnosis and monitoring of COVID-19. Clin Chem  2021; 68:204–13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8522398</ArticleId><ArticleId IdType="pubmed">34605900</ArticleId></ArticleIdList></Reference><Reference><Citation>Wick  KD, Leligdowicz  A, Willmore  A, et al.  Plasma SARS-CoV-2 nucleocapsid antigen levels are associated with progression to severe disease in hospitalized COVID-19. Crit Care  2022; 26:278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9472195</ArticleId><ArticleId IdType="pubmed">36104754</ArticleId></ArticleIdList></Reference><Reference><Citation>Yonker  LM, Gilboa  T, Ogata  AF, et al.  Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier. J Clin Invest  2021; 131;e149633.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8279585</ArticleId><ArticleId IdType="pubmed">34032635</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang  Y, Ong  CM, Yun  C, et al.  Diagnostic value of nucleocapsid protein in blood for SARS-CoV-2 infection. Clin Chem  2021; 68:240–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8436384</ArticleId><ArticleId IdType="pubmed">34358289</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang  W, Liu  W, Lin  J, et al.  Highly prevalent SARS-CoV-2 antigenemia in COVID-19 patients. Infect Dis Immun  2022; 2:193–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9295937</ArticleId><ArticleId IdType="pubmed">37520106</ArticleId></ArticleIdList></Reference><Reference><Citation>Shim  SR, Kim  S-J, Lee  J. Diagnostic test accuracy: application and practice using R software. Epidemiol Health  2019; 41:e2019007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6545496</ArticleId><ArticleId IdType="pubmed">30999739</ArticleId></ArticleIdList></Reference><Reference><Citation>Whiting  PF, Rutjes  AW, Westwood  ME, et al.  QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med  2011; 155:529–36.</Citation><ArticleIdList><ArticleId IdType="pubmed">22007046</ArticleId></ArticleIdList></Reference><Reference><Citation>Brasen  CL, Christensen  H, Olsen  DA, et al.  Daily monitoring of viral load measured as SARS-CoV-2 antigen and RNA in blood, IL-6, CRP and complement C3d predicts outcome in patients hospitalized with COVID-19. Clin Chem Lab Med  2021; 59:1988–97.</Citation><ArticleIdList><ArticleId IdType="pubmed">34455731</ArticleId></ArticleIdList></Reference><Reference><Citation>Brasen  C, Christensen  H, Olsen  D, et al.  Virus levels in blood is determining degree of severity in COVID-19 infection. Clinical Chemistry and Laboratory Medicine (CCLM)  2023; 61:s563–s770.</Citation></Reference><Reference><Citation>Epling  BP, Rocco  JM, Boswell  KL, et al.  Clinical, virologic, and immunologic evaluation of symptomatic coronavirus disease 2019 rebound following nirmatrelvir/ritonavir treatment. Clin Infect Dis  2023; 76:573–81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9619622</ArticleId><ArticleId IdType="pubmed">36200701</ArticleId></ArticleIdList></Reference><Reference><Citation>Kristiansen  S, Schmidt  LE, Hillig  A-BN, et al.  Diagnostic accuracy for a plasma SARS-CoV-2 nucleocapsid protein method. F1000Res  2022;.  11:732.</Citation></Reference><Reference><Citation>Lebedin  YS, Lyang  OV, Galstyan  AG, Panteleeva  AV, Belousov  VV, Rebrikov  DV. The importance of determining SARS-COV-2 N-ag serodiagnstics for the management of COVID-19 pneumonia in hospital settings. Bulletin of RSMU  2020. doi:10.24075/brsmu.2021.009. Accessed May 9, 2023.</Citation><ArticleIdList><ArticleId IdType="doi">10.24075/brsmu.2021.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu  B, Wu  Z, Liang  C, et al.  Development of a smartphone-based nanozyme-linked immunosorbent assay for quantitative detection of SARS-CoV-2 nucleocapsid phosphoprotein in blood. Front Microbiol  2021; 12:692831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8420716</ArticleId><ArticleId IdType="pubmed">34497592</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathur  S, Davidson  MC, Anglin  K, et al.  Evaluation of severe acute respiratory syndrome coronavirus 2 nucleocapsid antigen in the blood as a diagnostic test for infection and infectious viral shedding. Open Forum Infect Dis  2022; 9:XXX–XX.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9620332</ArticleId><ArticleId IdType="pubmed">36381627</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthay  ZA, Fields  AT, Wick  KD, et al.  Association of SARS-CoV-2 nucleocapsid viral antigen and the receptor for advanced glycation end products with development of severe disease in patients presenting to the emergency department with COVID-19. Front Immunol  2023; 14:1130821.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10070743</ArticleId><ArticleId IdType="pubmed">37026003</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann  A, Gökkaya  M, Dorgham  K, et al.  The association of cytokine profiles and SARS- coV- 2 viral load with COVID- 19 severity and mortality. Allergy  2021; 76(S110):424–582.</Citation></Reference><Reference><Citation>Peluso  MJ, Pickering  H, Chan  F, et al.  Differential association of cytomegalovirus with acute and post-acute COVID-19 [CROI abstract 273]. Top Antivir Med  2023:110.</Citation></Reference><Reference><Citation>Peluso  MJ, Swank  Z, Goldberg  SA, et al.  Plasma-based antigen persistence in the post-acute phase of sars-cov-2 infection [CROI abstract 282]. Top Antivir Med  2023:113.</Citation></Reference><Reference><Citation>Rouka  E, Kotsiou  OS, Perlepe  G, Pagonis  A, Pantazopoulos  I, Gourgoulianis  KI. Alanine aminotransferase serum levels in COVID-19 patients inversely correlate with SARS-CoV-2 antigen. Eur J Gastroenterol Hepatol  2021; 33(1S Suppl 1):e1080.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8734567</ArticleId><ArticleId IdType="pubmed">35048666</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu  Z, Wang  C, Liu  B, et al.  Smartphone-based high-throughput fiber-integrated immunosensing system for point-of-care testing of the SARS-CoV-2 nucleocapsid protein. ACS Sens  2022; 7:1985–95.</Citation><ArticleIdList><ArticleId IdType="pubmed">35766020</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutjes  AW, Reitsma  JB, Vandenbroucke  JP, Glas  AS, Bossuyt  PM. Case–control and two-gate designs in diagnostic accuracy studies. Clin Chem  2005; 51:1335–41.</Citation><ArticleIdList><ArticleId IdType="pubmed">15961549</ArticleId></ArticleIdList></Reference><Reference><Citation>Owusu  D, Pomeroy  MA, Lewis  NM, et al.  Persistent SARS-CoV-2 RNA shedding without evidence of infectiousness: a cohort study of individuals with COVID-19. J Infect Dis  2021; 224:1362–71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7989388</ArticleId><ArticleId IdType="pubmed">33649773</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhoads  D, Peaper  DR, She  RC, et al.  College of American Pathologists (CAP) Microbiology Committee perspective: caution must be used in interpreting the cycle threshold (ct) value. Clin Infect Dis  2021; 72:e685–6.</Citation><ArticleIdList><ArticleId IdType="pubmed">32785682</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilber  E, Piantadosi  A, Babiker  A, et al.  Nucleocapsid antigenemia in patients receiving anti-CD20 therapy with protracted COVID-19. Open Forum Infect Dis  2022; 9:XXX–XX.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9416058</ArticleId><ArticleId IdType="pubmed">36043176</ArticleId></ArticleIdList></Reference><Reference><Citation>Wee  LE, Tan  JY, Ko  KK, et al.  Detection of viable SARS-CoV-2 in deep respiratory specimens despite negative nasopharyngeal SARS-CoV-2 RT-PCR: occult COVID-19 as an unsuspected cause of pulmonary infiltrates in immunocompromised patients. IDCases  2022; 30:e01611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9395297</ArticleId><ArticleId IdType="pubmed">36032521</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaul  DR, Valesano  AL, Petrie  JG, et al.  Donor to recipient transmission of SARS-CoV-2 by lung transplantation despite negative donor upper respiratory tract testing. Am J Transplant  2021; 21:2885–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8014875</ArticleId><ArticleId IdType="pubmed">33565705</ArticleId></ArticleIdList></Reference><Reference><Citation>Dioverti  V, Salto-Alejandre  S, Haidar  G. Immunocompromised patients with protracted COVID-19: a review of “long persisters.”  Curr Transplant Rep  2022; 9:209–18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9660019</ArticleId><ArticleId IdType="pubmed">36407883</ArticleId></ArticleIdList></Reference><Reference><Citation>Machkovech  HM, Hahn  AM, Garonzik Wang  J, et al.  Persistent SARS-CoV-2 infection: significance and implications. Lancet Infect Dis  2024; 24:e453–62.</Citation><ArticleIdList><ArticleId IdType="pubmed">38340735</ArticleId></ArticleIdList></Reference><Reference><Citation>Haidar  G, Mellors  JW. Improving the outcomes of immunocompromised patients with coronavirus disease 2019. Clin Infect Dis  2021; 73:e1397–401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8135839</ArticleId><ArticleId IdType="pubmed">33949644</ArticleId></ArticleIdList></Reference><Reference><Citation>Fandiño-Devia  E, Rodríguez-Echeverri  C, Cardona-Arias  J, Gonzalez  A. Antigen detection in the diagnosis of histoplasmosis: a meta-analysis of diagnostic performance. Mycopathologia  2016; 181:197–205.</Citation><ArticleIdList><ArticleId IdType="pubmed">26559429</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou  T-Y, Wang  S-H, Liang  S-X, Jiang  W-X, Luo  D-D, Huang  D-H. The screening performance of Serum 1,3-beta-D-glucan in patients with invasive fungal diseases: a meta-analysis of prospective cohort studies. PLoS One  2015; 10:e0131602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4493111</ArticleId><ArticleId IdType="pubmed">26146829</ArticleId></ArticleIdList></Reference><Reference><Citation>Leeflang  MM, Debets-Ossenkopp  YJ, Wang  J, et al.  Galactomannan detection for invasive aspergillosis in immunocompromised patients. Cochrane Database Syst Rev  2015; 2015:CD007394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6483812</ArticleId><ArticleId IdType="pubmed">26716951</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimada  T, Noguchi  Y, Jackson  JL, et al.  Systematic review and metaanalysis: urinary antigen tests for legionellosis. Chest  2009; 136:1576–85.</Citation><ArticleIdList><ArticleId IdType="pubmed">19318671</ArticleId></ArticleIdList></Reference><Reference><Citation>White  SK, Walker  BS, Hanson  KE, Schmidt  RL. Diagnostic accuracy of beta-d-glucan (fungitell) testing among patients with hematologic malignancies or solid organ tumors: a systematic review and meta-analysis. Am J Clin Pathol  2019; 151:275–85.</Citation><ArticleIdList><ArticleId IdType="pubmed">30307463</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>